← Back to Search

Neurotoxin

OLD (4 U per 0.1 mL) for Frown Lines

Phase < 1
Waitlist Available
Led By John Joseph, MD
Research Sponsored by Clinical Testing of Beverly Hills
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 180 days
Awards & highlights

Study Summary

This study is evaluating whether BOTOX injections can reduce the severity of dynamic glabellar lines.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~180 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 180 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response Duration
Secondary outcome measures
Change from Baseline Score
Change in Frontalis Function
Investigator Live Assessment (At Rest)
+3 more

Trial Design

2Treatment groups
Active Control
Group I: OLD (4 U per 0.1 mL)Active Control1 Intervention
The total BOTOX dose will be 20U divided into 5 injections. Each injection will receive a total of 0.5 mL.
Group II: COLD (4 U per 0.02 mL group)Active Control1 Intervention
The total BOTOX dose will be 20U divided into 5 injections. Each injection will receive a total of 0.1 mL.

Find a Location

Who is running the clinical trial?

Clinical Testing of Beverly HillsLead Sponsor
3 Previous Clinical Trials
100 Total Patients Enrolled
AllerganIndustry Sponsor
781 Previous Clinical Trials
276,529 Total Patients Enrolled
1 Trials studying Frown Lines
101 Patients Enrolled for Frown Lines
John Joseph, MDPrincipal InvestigatorClinical Testing of Beverly Hills
6 Previous Clinical Trials
158 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Plastic and Reconstructive SurgeryJournal
Consensus Recommendations on the Use of Botulinum Toxin Type A in Facial Aesthetics
Carruthers, Jean, Steven Fagien, and Seth L. Matarasso. 2004. “Consensus Recommendations on the Use of Botulinum Toxin Type A in Facial Aesthetics”. Plastic and Reconstructive Surgery. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/01.prs.0000144795.76040.d3.
clinicaltrials.govStudy
Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines
2021. "Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05083286.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top